MQS Management’s Biogen BIIB Stock Holding History

MQS Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3,206	Closed	-$449K	–	425
2025 Q3	$449K	Sell	3,206 -611	-16%	-$82.6K	0.26%	145
2025 Q2	$479K	Buy	3,817 +2,030	+114%	+$253K	0.26%	133
2025 Q1	$245K	Buy	+1,787	New	+$255K	0.14%	319
2024 Q4	–	Sell	-3,256	Closed	-$631K	–	71
2024 Q3	$631K	Buy	+3,256	New	+$681K	0.35%	78
2024 Q2	–	Sell	-2,010	Closed	-$433K	–	438
2024 Q1	$433K	Buy	+2,010	New	+$471K	0.25%	149

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

MQS Management's BIIB Position: Q4 2025 in Review

MQS Management sold out of Biogen (BIIB) in Q4 2025, closing a stake of 3,206 shares — an estimated $449K sold.

MQS Management first reported a position in BIIB in Q1 2024 and held it in 5 quarters. The position peaked at $631K in Q3 2024. 1,000 funds tracked by Wall St. Rank hold BIIB as of Q4 2025.

MQS Management reported no remaining Biogen position as of Q4 2025 after selling out during the quarter.
MQS Management sold 3,206 Biogen shares in Q4 2025, an estimated $449K.
MQS Management first reported a position in Biogen in Q1 2024 and held it in 5 quarters.
MQS Management's Biogen position peaked at $631K in Q3 2024.
1,000 funds tracked by Wall St. Rank held Biogen as of Q4 2025.

Based on MQS Management's 13F filing for Q4 2025, filed 9 Feb 2026.